Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

32 questions · 32 findings · 7 reviews · Oral Health

No studies found 4 · 12.5%GRADE not reported 24 · 75%Very low 3 · 9.4%Low 0 · 0%Moderate 1 · 3.1%High 0 · 0%

Colchicine (0.5 mg three times per day) vs placebo

Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
  • There was a greater percentage of treatment interruptions in the colchicine group due to gastrointestinal adverse effects (Fisher's exact test P=0.009). The review noted potential evidence of harm at a dose of 1.5 mg…
    1 study · 43 participants
    GRADE not reported

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs Montelukast (leukotriene receptor antagonist)

Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review

Pilocarpine lozenge (3 mg or 5 mg) vs placebo control

Dry mouth (xerostomia) · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…
1 finding from 1 review
  • Interventions for the management of dry mouth: topical therapies 2011 · Cochrane All outcomes
    Single dose (up to 3 hours)
    Taweechaisupapong 2006 (crossover): participants reported a statistically significant improvement in oral dryness after both 3 mg and 5 mg pilocarpine lozenges vs placebo (P <= 0.05); no usable data presented. No…
    1 study · 33 participants
    GRADE not reported

Pilocarpine lozenge (3 mg or 5 mg) vs placebo control

Salivary flow rate · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…
1 finding from 1 review

Fluoride-containing dental care products (mainly fluoride toothpaste; one study also included fluoride varnish) vs Dietary fluoride sources (drinking water, beverages, food)

Contribution of dental care products to total daily fluoride intake (TDFI) · Humans using fluoride-containing dental care products; 28 included studies, mostly young children, only two studies in adults (aged…

Fluoride-containing dental care products (mainly toothpaste) contributed on average 38% (SD 27%) of total daily fluoride intake, regardless of tap-water fluoride level or age (ungraded; descriptive synthesis, no meta-analysis).

1 finding from 1 review

Topical NSAID (ketoprofen lysinate mouthwash, 160 mg) vs Topical NSAID (benzidamine hydrochloride mouthwash, 22.5 mg)

Failure to complete orthodontic treatment due to pain · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)

The review found no eligible studies for this question.

1 finding from 1 review

Topical NSAID (ketoprofen lysinate mouthwash, 160 mg) vs Topical NSAID (benzidamine hydrochloride mouthwash, 22.5 mg)

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
1 finding from 1 review

Keratinocyte GF 50 mg vs Keratinocyte GF 25 mg

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Keratinocyte GF 50 mg showed no clear difference in oral mucositis (moderate to severe) compared with keratinocyte GF 25 mg; GRADE not reported.

1 finding from 1 review

Keratinocyte GF 50 mg vs Keratinocyte GF 25 mg

Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Keratinocyte GF 50 mg showed no clear difference in oral mucositis (severe) compared with keratinocyte GF 25 mg; GRADE not reported.

1 finding from 1 review